Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bausch Health Companies Inc. | Amiselimod S1P6 Modulator | Ulcerative Colitis | Phase 3 | Trial Planned | Oral | Gastroenterology |
| Bausch Health Companies Inc. | RELISTOR (methylnaltrexone bromide: MNTX) | Resectable head and neck squamous cell carcinoma | Phase 2 | Enrollment Initiation | Subcutaneous | Oncology |
| Bausch Health Companies Inc. | IDP-124 | Atopic Dermatitis | Phase 3 | Trial Completed | Topical | Immunology |
| Bausch Health Companies Inc. | larsucosterol (DUR-928) - (AHFIRM) | Alcoholic hepatitis (AH) | Phase 3 | Trial Planned | Intravenous | Gastroenterology |
| Bausch Health Companies Inc. | IDP-120 | Acne | Phase 3 | Trial Completed | Topical | N/A |
| Bayer AG ADR | KERENDIA (finerenone) - (FINE-ONE) | Type 1 Diabetes and Chronic Kidney Disease | Phase 3 | Data Released | Oral | Endocrinology |
| Bayer AG ADR | MIRENA (levonorgestrel-releasing intrauterine system) - (SUNFLOWER) | Nonatypical endometrial hyperplasia (NAEH) | Phase 3 | Ongoing | Intrauterine | Women's Health |
| Bayer AG ADR | BAY 3401016 - (ASSESS) | Alport Syndrome | Phase 2a | Enrollment Initiation | oral | Genetic Disorder |
